Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Jung S, Parajuli A, Yu CS, et al. Sensitivity of various evaluating modalities for predicting a pathologic complete response after preoperative chemoradiation therapy for locally advanced rectal cancer. Ann Coloproctol. 2019;35(5):275–281. doi:10.3393/ac.2019.01.07
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–844. doi:10.1016/S1470-2045(10)70172-8
   PubMed Web of Science ®Google Scholar
• Rubio J, Cristóbal I, Santos A, et al. Low MicroRNA-19b expression shows a promising clinical impact in locally advanced rectal cancer. Cancers. 2021;13(6):1456. doi:10.3390/cancers13061456
   PubMed Web of Science ®Google Scholar
• Cui Y, Yang X, Shi Z, et al. Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2019;29(3):1211–1220. doi:10.1007/s00330-018-5683-9
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595. doi:10.1182/blood-2009-02-206870
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292
   PubMed Web of Science ®Google Scholar
• Hendry S, Russell PA, John T. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24:235.
   PubMed Web of Science ®Google Scholar
• Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35(3):25. doi:10.1007/s12032-018-1080-0
   PubMed Web of Science ®Google Scholar
• Chan LF, Sadahiro S, Suzuki T, et al. Tissue-infiltrating lymphocytes as a predictive factor for recurrence in patients with curatively resected colon cancer: a propensity score matching analysis. OCL. 2020;98(10):680–688. doi:10.1159/000506706
   Google Scholar
• Millar E, Browne L, Slapetova I, et al. TILs immunophenotype in breast cancer predicts local failure and overall survival: analysis in a large radiotherapy trial with long-term follow-up. Cancers. 2020;12(9):2365. doi:10.3390/cancers12092365
   PubMed Web of Science ®Google Scholar
• Fusco N, Vaira V, Righi I, et al. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer. 2020;150:53–61. doi:10.1016/j.lungcan.2020.09.026
   PubMed Web of Science ®Google Scholar
• Jiang D, Liu Y, Wang H, et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma. Sci Rep. 2017;7(1):44823. doi:10.1038/srep44823
   PubMedGoogle Scholar
• Xu B, Salama AM, Valero C, et al. Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs). Pathol Res Pract. 2021:153473. doi:10.1016/j.prp.2021.153473
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271. doi:10.1093/annonc/mdu450
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu M, Chen J, et al. Prognostic value of the FOXK family expression in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Onco Targets Ther. 2020;13:9185–9201. doi:10.2147/OTT.S255956
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guan B, Wu Y, et al. LncRNAs signature associated with chemoradiotherapy response and prognosis in locally advanced rectal cancer; 2021. doi:10.21203/rs.3.rs-452503/v1.
   Google Scholar
• Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–246. doi:10.1111/codi.13207
   PubMed Web of Science ®Google Scholar
• Chen W, Mao L, Li L, et al. Predicting treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer using amide proton transfer MRI combined with diffusion-weighted imaging. Front Oncol. 2021;11:2367. doi:10.3389/fonc.2021.698427
   Web of Science ®Google Scholar
• Wang A, Zhang J, Tan C, et al. Stromal organization as a predictive biomarker of response to neoadjuvant therapy in locally advanced rectal cancer. J Gastrointest Surg. 2021;25(8):2116–2118. doi:10.1007/s11605-021-04920-7
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Tanaka N, Kiyotani K, et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106(10):1381–1392. doi:10.1002/bjs.11179
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Gotoh O, Tanaka N, et al. T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother. 2021;70(2):509–518. doi:10.1007/s00262-020-02705-6
   PubMed Web of Science ®Google Scholar
• Shaban M, Khurram SA, Fraz MM, et al. A novel digital score for abundance of tumour infiltrating lymphocytes predicts disease free survival in oral squamous cell carcinoma. Sci Rep. 2019;9(1):13341. doi:10.1038/s41598-019-49710-z
   PubMedGoogle Scholar
• Linder N, Taylor JC, Colling R, et al. Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. J Clin Pathol. 2019;72(2):157–164. doi:10.1136/jclinpath-2018-205328
   PubMed Web of Science ®Google Scholar
• Sawada R, Akiyoshi T, Kitagawa Y, et al. Systemic inflammatory markers combined with tumor-infiltrating lymphocyte density for the improved prediction of response to neoadjuvant chemoradiotherapy in rectal cancer. Ann Surg Oncol. 2021. doi:10.1245/s10434-021-09975-z
   Web of Science ®Google Scholar
• Shinto E, Omata J, Sikina A, et al. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer. BJS Open. 2020;4(2):301–309. doi:10.1002/bjs5.50251
   PubMed Web of Science ®Google Scholar